Ketamine-derived nasal spray treating Phoenix patients with severe depression
A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...
Fortune14d
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
pharmaphorum14d
NICE rejects J&J’s Spravato for treatment-resistant depression
The UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal spray Spravato on the NHS, because of cost and clinical concerns.
verywellhealth15d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
REMS requires patients to administer Spravato at a clinic in the presence of a physician. “We probably know more about the adverse event profile of intranasal ketamine than, I may argue, any ...
Healthline19d
Side Effects of Camzyos: What You Need to Know
The FDA requires REMS programs for certain medications to help make sure they’re used safely. Your doctor must be certified by the REMS program in order to prescribe Camzyos. And you’ll only ...
Too Old to Operate20d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
PopSugar21d
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Because Spravato comes with the potential for misuse, it's only available through a restricted distribution system under a Risk Evaluation and Mitigation Strategy (REMS). Meaning, you have to go ...
Daily21d
JnJ Spravato gets USFDA nod as monotherapy for adults with treatment-resistant depression
Titusville: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, making this ...
WXYZ21d
FDA approves Spravato as first stand-along nasal spray to treat drug-resistant depression
There’s also the chance it could be misused. Because of this, Spravato is only available at certified treatment centers where patients are closely monitored. You won’t be able to pick it up at ...
Yahoo Finance21d
J&J’s Spravato receives FDA label expansion for depression monotherapy
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not ...
U.S. News & World Report21d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...